🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

49+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 9 of 49 recruiting trials for “extranodal-nasal-nkt-cell-lymphoma”

Phase 2RecruitingNCT05941156 ↗

Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

🏥 The Affiliated Hospital of Xuzhou Medical University📍 1 site📅 Started May 2023View details ↗
Phase 2RecruitingNCT05477264 ↗

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

🏥 Won Seog Kim📍 1 site📅 Started Mar 2023View details ↗
Phase 4RecruitingNCT06134284 ↗

Clinical Study of OR for Second-line Treatment of Refractory MZL

👨‍⚕️ Chen, First Affiliated Hospital of Ningbo University📍 3 sites📅 Started Jan 2023View details ↗
Phase 2RecruitingNCT04417166 ↗

Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

👨‍⚕️ Stefano Luminari, MD, Ematologia, AUSL IRCCS Reggio Emilia📍 2 sites📅 Started Feb 2022View details ↗
Phase 3RecruitingNCT04834024 ↗

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

🏥 Beijing Mabworks Biotech Co., Ltd.📍 1 site📅 Started Jun 2021View details ↗
Phase 3RecruitingNCT04365036 ↗

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

🏥 Sun Yat-sen University📍 1 site📅 Started May 2020View details ↗
Phase 2RecruitingNCT02859402 ↗

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

🏥 Keimyung University Dongsan Medical Center📍 2 sites📅 Started Dec 2016View details ↗
Phase 2RecruitingNCT02974647 ↗

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

👨‍⚕️ Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center📍 10 sites📅 Started Nov 2016View details ↗
Phase 1RecruitingNCT01555892 ↗

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

👨‍⚕️ Helen E Heslop, MD, Baylor College of Medicine📍 3 sites📅 Started Jan 2013View details ↗
← PreviousPage 3 of 3

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →